

# HOBART GROUP *at a Glance*

---

Our aim is to help develop new and improved ways to manage growing global demands related to chronic disease. We develop and commercialize medical technologies, specifically targeting chronic disease markets with significant unmet needs. With group offices in Hamilton (Bermuda), Geneva (Switzerland) and Beijing (China), our growing portfolio of companies covers the areas of cardiology, diabetes, oncology, neurology and rehabilitation.

---

## Innovation benefiting humanity

### **200+ employees**

across our companies

### **1,000+ patents**

& applications by our inventors

### **\$200M+**

**investments** in our portfolio

### **10+ products launched**

across our companies

### **1M+ patients treated**

with products developed by us

### **\$1B+ exits**

in a dozen companies

---

## The team

Our portfolio is managed by a team of experienced industry executives:

**Shlomo Ben-Haim MD**, Founder and Chairman

**Simos Kedikoglou MD**, CEO of Impulse Dynamics and former Corporate VP of Business Development at Boston Scientific

**Adrian Gilmore**, CEO of MetaCure and former President of Terumo Medical Products

## 9 Hobart companies

### **Impulse Dynamics**

Dedicated to offering innovative medical device solutions for the treatment of chronic heart failure.

### **MetaCure**

Dedicated to the development and commercialization of a minimally-invasive treatment for type 2 diabetes.

### **Motorika**

Develops and commercializes robot-assisted solutions to meet the therapeutic needs of patients suffering from variety of neurological conditions.

### **FlowMedic**

Developer of innovative miniaturized portable leg compression devices for the treatment of PAD and prevention of DVT.

### **Molecular Dynamics**

Developing innovative imaging technologies and advanced clinical applications.

### **Renal Dynamics**

Dedicated to treating hypertension through its third-generation renal denervation system.

### **EPD Solutions**

Committed to improving the efficacy and efficiency of minimally-invasive catheter-based procedures for the treatment of cardiac arrhythmia.

### **Lavita Technologies**

An early stage neuromodulation company, focused on development of the Nexion™ system for treatment of autoimmune inflammatory diseases.

### **OncoD**

An early stage company developing a suite of navigation and ablation tools for treating solid tumors.

### **Our track record: 8 public and acquired companies**

Novocure / Corindus / Disc-O-Tech Biosense-Webster / Radiancy Spectrum Dynamics / InStent X-technologies